Drug Development Time Is Five Years From Target To NDA, Glaxo's Sykes Says

24 Jan 2000
News

The Pink Sheet pinkeditor@informa.com

Executive Summary

Glaxo SmithKline's development timeline from discovery of a novel target to NDA filing would be as little as five years, Glaxo Wellcome Chairman Richard Sykes maintained during a Jan. 18 briefing on the Glaxo SmithKline merger in New York City.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS035471

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS035471

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Drug Development Time Is Five Years From Target To NDA, Glaxo's Sykes Says

News

Executive Summary

Related Content

FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB

FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert